BioXcel Therapeutics, Inc. (BTAI) Debt by Year
BioXcel Therapeutics, Inc. carried $84.7M in long-term debt against $28.4M in cash and equivalents at the end of fiscal year 2025. This represents a decrease of 17.4% from the prior fiscal year. The table below carries 9 fiscal years, from 2017 to 2025, and the quarters BioXcel Therapeutics, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
BTAI Debt & Cash by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
BTAI Debt & Cash by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | $0-100.0% | $77.9M-22.1% | $84.7M-17.4% | $92.3M-11.6% | $97.5M-5.4% | $99.9M-1.7% | $102.5M+1.9% | $104.4M+5.4% | $103.0M+6.4% | $101.6M+6.9% | $100.6M+8.1% | $99.1M+8.1% |
| Cash & Equivalents | $12.8M-26.3% | $17.2M-44.6% | $28.4M-4.8% | $36.2M-10.4% | $17.4M-69.0% | $31.0M-58.2% | $29.9M-54.2% | $40.4M-55.1% | $56.3M-55.9% | $74.1M-55.2% | $65.2M-66.3% | $90.0M-61.3% |
What long-term debt means
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date.
More BioXcel Therapeutics, Inc. financials
Frequently Asked Questions
What was BioXcel Therapeutics, Inc.'s long-term debt in fiscal year 2025?
BioXcel Therapeutics, Inc. carried $84.7M in long-term debt against $28.4M in cash and equivalents at the end of fiscal year 2025.
How fast is BioXcel Therapeutics, Inc.'s long-term debt growing?
BioXcel Therapeutics, Inc. (BTAI) long-term debt fell by 17.4% year over year, from $102.5M to $84.7M in fiscal year 2025.
What was BioXcel Therapeutics, Inc.'s long-term debt in the most recent quarter?
BioXcel Therapeutics, Inc. (BTAI) reported $0 in long-term debt in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier.
What does long-term debt mean on a financial statement?
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date. This page lists what BioXcel Therapeutics, Inc. (BTAI) reported on that line in every period on record.